Earnings Call, Conference Presentation
GLP-1s are shrinking some appetites; broader use poses a prickly challenge
- As of the recording date (May 19, 2026), GLP-1 penetration in the U.S. among obese, non-diabetic patients is estimated at 10%, representing approximately 10 million treated individuals.
- U.S. GLP-1 revenue is projected to reach $28 billion in 2026, with market estimates predicting 15 to 20 million patients (13–17% of the obese population) will be treated within the next two to three years.
- International markets currently trail U.S. adoption rates, though they now contribute roughly a 50-50 split to total category revenue.
- A deflationary pricing cycle is underway, driven by high consumer demand in the cash-pay channel and upcoming Medicare price points fixed by government agreements.
- Oral GLP-1 formulations are a primary growth driver, expected to democratize access by reducing medical stigma, eliminating refrigeration requirements, and improving patient adherence compared to injectables.
- Therapy adherence patterns show approximately 33% of users discontinue treatment within six months due to cost, tolerability, or preference, while roughly 40–45% remain on therapy for over one year.
- The next generation of GLP-1 drugs targets specific unmet needs, including the preservation of lean muscle mass and reduced gastrointestinal side effects like nausea and vomiting.
- Future market growth in GLP-1s will likely result in market share shifts among competitors rather than total market expansion, as new modalities compete directly with established entities.
- Packaged food companies have already incorporated negative terminal growth rates into valuations, potentially facing an additional 50 to 100 basis point reduction due to GLP-1 adoption.
- Sweet treats and salty snacks (particularly potato chips) are the most negatively impacted food categories, with volume declines attributed to both GLP-1 usage and prior aggressive pricing by manufacturers.
- Despite anecdotal evidence suggesting increased protein consumption, Cornell University study data indicates protein categories declined in line with the broader market, with no single protein sub-category showing statistically significant growth.
- Yogurt was the only food category in the Cornell study showing a potential upward trend, likely due to its higher protein content, ease of digestion, and suitability for patients experiencing stomach issues.
- Alcohol consumption data at the household level shows no net decline, though a shift occurred where wine and spirits consumption dropped while beer consumption remained flat, suggesting specific demographic changes within households.
- Future packaged food volume recovery is contingent on inflation relief and wage growth for low-income consumers, as current K-shaped economic conditions continue to suppress demand in staple categories.
- GLP-1 manufacturers face significant headwinds from a wave of new competitors entering the market in 2028–2029 and the introduction of generic semaglutide.
- Large-cap pharmaceutical companies with GLP-1 pipelines are currently trading at low multiples (around 9x forward earnings), reflecting market skepticism regarding the "show-me" nature of future pipeline innovation and reimbursement risks.
- Analysts anticipate the U.S. market may be nearing saturation, positioning international markets as the primary potential for future value capture, with scenarios where U.S. share is less than 50% of total peak sales.